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Abstract 
Although current immunosuppression protocols improve the efficacy of clinical 
allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and 
major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, 
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a cysteine protease, has the unique ability to cleave the extracellular domain of the 
MHC class I structure. We hypothesized that pretreatment of donor islets with papain 
would diminish the expression of MHC class I on islets, reducing allograft 
immunogenicity and contributing to prolongation of islet allograft survival. BALB/c 
islets pretreated with papain were transplanted into C57BL/6J mice as an acute 
allorejection model. Treatment with 1 mg/mL papain significantly prolonged islet 
allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated 
alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte 
reactions. Host T cell activation against allogenic islet cells was remarkably 
suppressed by pretreatment of donor islet cells with 10 mg/mL papain. Flow 
cytometric analysis was also performed to investigate the effect of papain treatment 
on the expression of MHC class I on islets. One or 10 mg/mL papain treatment 
reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets 
with papain suppresses MHC class I-mediated allograft rejection in mice and 
contributes to prolongation of islet allograft survival without administration of systemic 
immunosuppressants. These results suggest that pretreatment of human donor islets 
with papain may reduce the immunogenicity of the donor islets and minimize the 
dosage of systemic immunosuppressants required in a clinical setting. 
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Introduction 
Clinical allogenic islet transplantation has become an accepted procedure for 
treatment of type 1 diabetes mellitus.1-3 Furthermore, current combinatorial therapy 
by T cell depletion and anti-tumor necrosis factor-α antibody treatment has certainly 
enhanced graft survival.4 However, functional decline and graft loss remain barriers 
for successful islet transplantation. Furthermore, the required doses of systemic 
immunosuppressive drugs should be decreased as low as possible for reducing side 
effects such as infection and oncogenesis.5-7 
Allorejection caused by T cell-mediated immune reactions is one of the major 
problems that lead to islet graft loss. There is no sufficient protocol to control 
allorejection to date.6 Alloreaction occurs through major histocompatibility complex 
(MHC) class I and II molecules that are both expressed on the cell surface. MHC 
class I molecules are expressed on whole nucleated cells of the body, whereas MHC 
class II molecules are only expressed on the surface of certain types of immune cells, 
including macrophages and dendritic cells, which are known as professional 
antigen-presenting cells. Host CD8+ T cells recognize allo-MHC class I-peptide 
complexes as alloantigens through T cell receptors, while host CD4+ T cells recognize 
allo-MHC class II similarly.  
The mechanism of allorecognition is divided into three pathways including direct, 
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indirect and semidirect.8-11 Among the three pathways, the direct pathway, which 
involves both allo-MHC class I and II antigens, plays a crucial role in acute 
alloreactions.12 Host CD8+ T cells, the main effector cells of this phase, recognize 
allo-MHC class I molecules on grafts and elicit a destructive immune response.13 
Makhlouf et al. showed that MHC class I-CD8+ T cell-mediated reactions are more 
involved in islet allograft rejection than MHC class II-CD4+ T cell reactions in C57BL/6 
mice.14 Markmann et al. demonstrated a significant improvement of allograft survival 
in mice with MHC class I-deficient islets induced by gene disruption.15 Moreover, 
some donor MHC class I-removal strategies have shown successful outcomes in 
cellular transplantation such as insulin-secreting islets of Langerhans and fetal pig 
neuron transplants in animal models.16-23 In the present study, we explored a more 
applicable method to reduce MHC class I expression on islets. 
Papain is a sulfhydryl protease isolated from the surface of the green fruit of papaya, 
which is known for its unique ability to cleave the extracellular domain of the MHC 
class I heavy chain.24-26 Galati et al. showed a papain dose-dependent removal effect 
on MHC class I from mouse lymphocytes in vitro.27 Moreover, Mera et al. reported 
that papain cleaves human leukocyte antigen class I from human lymphocytes in a 
dose-dependent manner and inhibits mixed lymphocyte reactions (MLRs) by reducing 
immunogenicity in vitro.28 From these back grounds, we hypothesized that 
  
6 
 
pretreatment of donor islets with papain would diminish the expression of MHC class I 
on islets, reducing allograft immunogenicity and contributing to prolongation of islet 
allograft survival in mice. 
Results 
Papain pretreatment prolongs allograft survival of islet transplantation  
We initially investigated the effects of papain pretreatment of islets on allograft 
survival in an acute rejection model by transplanting BALB/c islets into C57BL/6J 
mice. As shown in Figure 1A and 1B, the 1 mg/mL papain treatment group showed 
the longest engraftment among the four groups (p<0.001). The median survival times 
(MSTs) of 0 (n=10), 0.1 (n=10), 1 (n=11), and 10 mg/mL (n=5) papain groups were 19, 
19, 26, and 12 days, respectively (Table 1). A significant difference in MST was 
observed between 0 and 1 mg/mL papain treatment groups (p=0.0088). Moreover, 
the mean graft survival of 0 and 1 mg/mL papain groups was 20.4±2.0 and 54.2±13.4 
days (mean±SE), respectively (p<0.05). Two of 10 mice in the 0.1 mg/mL papain 
treatment group and 3 of 11 mice in the 1 mg/mL papain treatment group remained 
normoglycemic until 120 days after transplantation. The 0.1 mg/mL papain treatment 
showed a higher graft survival rate than the 0 mg/mL papain control, but the MST was 
not prolonged.  
Nephrectomy was performed on the recipient mice at 120 days after transplantation. 
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After nephrectomy, all mice became hyperglycemic, indicating that the 
normoglycemia was maintained by the islet grafts (Figure 1A).  
Histological examinations revealed intact islets in the 1 mg/mL papain treatment 
group at up to 120 days after transplantation. In contrast, severe infiltration of 
mononuclear cells and degenerated islets were observed in the 0 mg/mL papain 
group at 14 days after transplantation (Figure 1C). Few Foxp3-positive regulatory T 
cells (Tregs) were observed in both 0 and 1 mg/mL papain groups (Figure 1C). 
Papain treatment of islet cells inhibits allogenic lymphocyte proliferation in 
vitro 
To investigate the effects of papain pretreatment of BALB/c islets on C57BL/6J 
lymphocyte proliferation in vitro, we assessed lymphocyte proliferation by MTT 
assays. Single islet cells derived from BALB/c mice as stimulators were pretreated 
with papain. As shown in Figure 2, the proliferation of C57BL/6J lymphocytes against 
BALB/c islet cells pretreated with 10 mg/mL papain was significantly inhibited 
compared with 0 mg/mL papain at 24–120 h. However, there was no significant 
difference in lymphocyte proliferation between 0 and 1 mg/mL papain groups. These 
results indicated that treatment with 10 mg/mL papain inhibited lymphocyte activation 
against allogenic islet cells in vitro.  
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Papain treatment removes MHC class I molecules from islet cells 
Previously, Mera et al. had reported that papain diminishes human leukocyte antigen 
class I molecules on the surface of human lymphocytes in a dose-dependent manner 
in vitro.28 To investigate whether papain performs cleavage of MHC class I on BALB/c 
mouse islet cells in vitro, we analyzed the expression of MHC class I by flow 
cytometric analysis. As shown in Figure 3, the proportions of MHC class I-positive 
islet cells treated with 0, 0.1, 1, or 10 mg/mL papain were 53.0, 55.4 (data not shown), 
43.5, and 39.9%, respectively. These results revealed a decrease in MHC class I 
expression on the surface of dispersed islets in a papain dose-dependent manner in 
vitro.  
Papain treatment inhibits MLRs in vitro 
To confirm the results of lymphocyte proliferation against allo-islets (Figure 2), we 
performed an MLR assay. BALB/c lymphocytes as stimulator cells were pretreated 
with papain to remove MHC class I before co-culture with responder T cells 
(C57BL/6J). The proliferation of responder CD3+ T cell was measured by flow 
cytometric analysis of CFSE with the decay of CFSE reflecting T cell proliferation. 
Briefly, the parent population is represented by a single peak (black). The cells 
proliferating from the parent population, i.e. the daughter population, are represented 
by three other linear histograms. Thus, the number of daughter generations as well as 
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the number of cells in each peak represent the proliferative activity. As shown in 
Figure 4A, the 0 mg/mL papain group showed a normal active proliferative response 
in the MLR. In contrast, the MLR response was remarkably inhibited by 10 mg/mL 
papain pretreatment of the stimulator cells between 24 and 96 h of culture. MTT 
assays were also performed at 72 h of culture to quantitatively evaluate the MLR. As 
a result, the proliferation of T cells was significantly inhibited by 10 mg/mL papain 
treatment compared with the 0 mg/mL papain group (Figure 4B), which corresponds 
to the results of flow cytometry. These results indicated that 10 mg/mL papain 
treatment suppressed the T cell alloresponse. 
Papain pretreatment has no negative effects on islet viability in vitro 
Finally, we analyzed the effect of papain treatment on islet viability. As shown in 
Figure 5A, there were few annexin V-positive islet cells treated with any papain 
concentration. Moreover, the PI-positive rate of islets treated with 0, 0.1, 1, or 10 
mg/mL papain was 98±1.95, 99±0.47, 99±0.27, and 98±0.7%, respectively (Figure 
5B). These results demonstrated that papain pretreatment has no negative effects on 
islet viability. 
Discussion 
Papain treatment has a long history as a useful analysis method of MHC class I 
structure and immunogenicity because of its well-known ability to cleave the MHC 
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class I heavy chain.26, 29-31 However, there has been no reports of allogenic cellular or 
organ transplantation using papain in animal models. Thus, it remains unclear how 
papain treatment to remove donor MHC class I on islet affects the outcome of 
allo-islet transplantation from the viewpoint of immunogenicity, especially 
alloreactions. In the present study, we demonstrated for the first time that papain 
treatment improves the outcomes of allo-islet transplantation, and revealed the 
inhibitory mechanism against the direct pathway involved in MHC class I-T 
cell-mediated alloreactions in mice. 
The results of this study clearly showed that donor islets pretreated with 1 mg/mL 
papain had significantly prolonged allograft survival in mice. More than 35% of the 1 
mg/mL papain-treated group showed graft survival for more 60 days. Furthermore, 
three of 11 mice in the 1 mg/mL papain-treated group showed remarkably longer 
allograft survival than 120 days after transplantation without immunosuppressive 
treatment. We assumed that these recipient mice might have completed immune 
tolerance at some point after transplantation. Generally, Tregs play an important role 
in controlling alloimmune tolerance, and some Treg-inducing strategies have 
achieved successful islet transplantation outcomes.32-35 Hence, we investigated the 
proportions of Tregs to mononuclear cells infiltrating into the graft site at day 120 (1 
mg/mL papain group) in comparison with grafts at day 14 of 0 and 1 mg/mL papain 
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groups by Foxp3 (Treg marker) staining. However, unexpectedly, there was no 
difference between the grafts at day 120 and 14. As a result, we concluded that 
papain treatment has little effect on Treg induction (Figure 1). However, our in vivo 
results are quite similar to those of Markmann et al. who reported preparation of MHC 
class I-deficient islets by gene disruption, although the recipient mice were BALB/c.15 
Thus, a strategy using papain may be comparable to a gene-targeting strategy.  
In vitro, we revealed that both 1 and 10 mg/mL papain treatment reduced MHC class 
I on the islet cell surface by flow cytometric analysis (Figure 3). Fifty-three percent of 
dispersed islet cells were positive for MHC class I, and 1 or 10 mg/mL papain 
treatment decreased MHC class I expression by 9.5 and 13.1%, respectively, 
compared with the control. These results suggested that cleavage of MHC class I on 
the islet cell surface by papain treatment is partial and temporary, because MHC 
class I may be re-expressed. Thus, papain pretreatment with systemic 
immunosuppression is thought to be an attractive therapy to reduce the use of 
systemic immunosuppressants.  
The lymphocyte proliferation assay to determine the effect of papain on alloreactions 
showed that host lymphocyte activation against allogenic islet cells was significantly 
suppressed by 10 mg/mL papain treatment (Figure 2). Furthermore, we confirmed 
that CD3+ T cell proliferation in MLRs was remarkably suppressed by 10 mg/mL 
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papain treatment (Figure 4). These results indicate that the decrease in MHC class I 
expression by papain treatment leads to suppression of T cell-mediated allorejection 
in mice. 
Interestingly, only pretreatment of donor islet cells with 10 mg/mL papain inhibited 
host T cell activation against allogenic islet cells in vitro. However, the 10 mg/mL 
papain group showed the shortest graft survival among the four groups. There are 
several possible reasons to explain this phenomenon. First, we designed in vitro 
experiments using single islet cells instead of islet clusters, because single cells 
facilitate analysis of the papain efficacy compared with islet clusters. On the other 
hand, islet clusters were used for in vivo experiments. A form of the islet cells, such as 
single cells or clusters may affect the effective papain dosage between in vivo and in 
vitro conditions. Therefore, both results are acceptable. Second, although 10 mg/mL 
papain treatment had no negative effects on islet viability in vitro (Figure 5), we found 
quite a few fragmented islets after 10 mg/mL papain treatment. Previously, Williams 
et al. reported that rat islets treated with papain became frangible and did not improve 
the outcome of islet transplantation in a syngenic model.36, 37 Thus, their report 
supports our results. It is presumed that such a fragmented islet structure may 
accumulate damage over time and eventually affect islet viability and functions 
negatively in vivo, which would not support long-term engraftment. Third, papain is 
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used to induce experimental pulmonary emphysema in animal models, because 
papain administration causes air space dimensions with destruction and thickening of 
lung tissue, which are involved in inflammation.38 Moreover, it has been previously 
reported that cytokines secreted from transplanted islets cause local inflammation 
that triggers the innate response and graft failure.39 Although we confirmed that the 
islets maintained their viability just after papain treatment in vitro (Figure 5), it is 
possible that islets pretreated with a higher papain concentration cause stronger 
inflammation by releasing high levels of cytokines, leading to early graft loss. Taking 
these ideas into consideration, we presume that 1 mg/mL papain is the optimal 
concentration to balance positive and negative effects of papain in islet 
transplantation. 
To date, some strategies to remove donor MHC class I have had success in cellular 
transplants including insulin-secreting islet transplants in murine models and even 
primates.17-20, 22 Markmann et al. revealed that MHC class I-deficient islets improve 
allograft survival in mice.15 Moreover, CD8+ T cell-deficient recipients show prolonged 
survival because they lack MHC class I-CD8+ T cell-mediated alloreactions.20 
Additionally, Coffman et al. concluded that genetic manipulations to reduce MHC 
class I expression may be effective to overcome some effects of MHC incompatibility 
in kidney transplants.40 These data strongly support our results and confirm that the 
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MHC class I system serves as an essential component of the allorejection that is 
common to both cellular and organ transplantations. Because it is a well-known fact 
that mammals, including humans, have similar MHC systems, the ultimate goal of this 
study is practical application to a clinical setting. Thus far, the elimination of MHC 
antigen expression by gene targeting is not practical as a clinical procedure for islet 
transplantation in terms of both technical and ethical issues. However, although the 
effect of papain is somewhat limited, this procedure is much more convenient and 
worth trialing at the clinical stage. Mera at el. showed that it is possible to maintain the 
activity of papain at 4 °C, suggesting that targeted enzymatic cleavage of donor MHC 
class I by papain has potential use in the whole organ transplant as well as tissue 
transplant setting.28 We also expect that papain pretreatment of allogenic grafts has 
the potential to decrease the required doses of systemic immunosuppressants. From 
this viewpoint, we propose combinatorial therapy with papain pretreatment of islets 
and low-dose systemic immunosuppressive drugs. Recently, Brooks et al. reported 
that antibody-mediated allo-rejection was important and caused by antibodies against 
mismatched donor HLA-A2 (MHC class I) in the recipients after transplantation.41 
They revealed that MHC class I is a crucial antigen not only for cellular immunity but 
also humoral immunity. Thus, the MHC class I molecule as an immune antigen may 
have deeper implications going forward. 
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In conclusion, pretreatment of donor islets with papain suppresses MHC class 
I-mediated allograft rejection in mice and contributes to the prolongation of islet 
allograft survival without administrating systemic immunosuppressants. These results 
suggest that pretreatment of human donor islets with papain may reduce the 
immunogenicity of the donor islets and minimize the dosage of systemic 
immunosuppressants required in a clinical setting. 
Materials and Methods 
Animals 
Male BALB/c (H-2d) and C57BL/6J (H-2b) mice were purchased from Charles River 
Japan and CLEA Japan Inc., respectively. All mice were maintained under specific 
pathogen-free conditions. Recipient C57BL/6J mice were applied to experiments at 
10–11 weeks of age. Diabetes was induced in the recipients by intravenous injection 
of streptozotocin (180 mg/kg body weight) (Sigma-Aldrich Co. S0130). Mice with 
persistent nonfasting blood glucose levels above 400 mg/dL at 2–3 days after 
streptozotocin injection were considered diabetic and used as transplant recipients. 
The experiments were approved by our Institutional Animal Care and Use Committee. 
Islet isolation  
Donor islets from BALB/c mice were isolated by the static digestion method using 
Type V collagenase (Sigma-Aldrich Co. C9263) and then separated by centrifugation 
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on Ficoll-Conray gradients.42 Islets of 150–250 μm in diameter were hand selected 
using a Pasteur pipette with the aid of a dissecting microscope. Isolated islets were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific 
11885-084) supplemented with 10% fetal bovine serum (GE Healthcare 172012) and 
1× Antibiotic-Antimycotic (Thermo Fisher Scientific 15240-062) overnight before 
transplantation. 
Papain preparation  
To display papain enzymatic activity from papaya latex (Sigma-Aldrich Co. P4762), 
two papain activating agents, L-cysteine (Sigma-Aldrich Co. 168149) and EDTA 
(Sigma-Aldrich Co. EDS) were required. Low glucose (1 g/L) DMEM supplemented 
with 0.05 M L-cysteine and 0.02 M EDTA, adjusted to pH 8.0 by 5 M NaOH was 
prepared freshly.28 Papain has excellent solubility to produce a high concentration 
solution. Papain at 0 (control), 0.1, 1, and 10 mg/mL was used for islet treatment. 
Papain pretreatment and islet transplantation 
Recipient mice were divided into four groups: 0, 0.1, 1, and 10 mg/mL papain groups. 
Prior to islet transplantation, 200 hand-picked islets were pretreated with each papain 
concentration at 37 °C for 15 min and then transplanted under the left kidney capsule 
(KC) of recipient mice. 
Nonfasting blood glucose levels and body weight were monitored three times a 
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week in all recipients until 120 days after islet transplantation. Blood glucose was 
measured using a GlucoCard DIAmeter (Arkray).     
Normoglycemia after transplantation was defined as two consecutive blood glucose 
level readings below 200 mg/dL. Graft rejection was defined as two consecutive 
hyperglycemias over 400 mg/dL. The first day confirmed as hyperglycemia was 
defined as the day of rejection. Nephrectomy was performed in recipients with 
functional grafts at more than 120 days after transplantation to ensure a normal 
glucose level had been maintained by the islet allograft.  
Immunohistochemistry 
Islet grafts with the kidney were fixed in 10% formaldehyde, processed, and 
embedded in paraffin. The sections were cut into 3 μm-thick sections and stained with 
hematoxylin-eosin (HE) or a Guinea pig anti-mouse insulin antibody (DAKO 
A056401) and rabbit anti-guinea pig secondary antibody (abcam ab97152) with a 
Warp Red™ Chromogen Kit (BIOCARE MEDICAL BRR806AH) in the presence of 
alkaline phosphatase for histochemical detection of insulin localization.43, 44  
Foxp3 staining was performed using an anti-Mouse/Rat Foxp3 antibody (Affymetrix 
eBioscience 14-5773-80) visualized by the chromogen diaminobenzidine and 
counterstaining with hematoxylin.  
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Lymphocyte proliferation assay 
To analyze the activity of host lymphocytes against donor islet cells in vitro, BALB/c 
islet cells with or without papain pretreatment and C57BL/6J lymphocytes were 
co-cultured as a lymphocyte proliferation assay. For inducing immunological 
sensitization in recipient C57BL/6J mice, BALB/c islets were transplanted under the 
KC of the recipient C57BL/6J mice 10 days before harvesting splenocytes, and then 
the harvested splenocytes were used as responder cells. Donor islets were isolated 
from BALB/c mice, cultured at 24 °C for 24 h, and then dissociated into single cells. 
After incubation at 37 °C for 24 h, the dispersed islet cells were treated with 0, 1 or 10 
mg/mL papain at 37 °C for 15 min and used as stimulator cells. Then, stimulator cells 
(1×104 cells) and responder cells (5×105 cells) were co-cultured in RPMI 1640 
supplemented with 10% fetal bovine serum, 55 M 2-mercaptoethanol, 100 U/mL 
penicillin, and 100 g/mL streptomycin in 96-well V-bottomed plates (total volume: 
200 μl at 37 °C and a humidified atmosphere with 5% CO2). Proliferation was 
measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
assays as a quantitative analysis using a Cell Counting Kit-8 (DOJINDO 
MOLECULAR TECHNOLOGIES, INC 347-07621) at 24, 48, 72, 96, and 120 h. 
Flow cytometric analysis  
Isolated islets were cultured at 24 °C overnight and then dissociated into single cells 
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by incubation with 0.04% EDTA and dispase I (GODO SHUSEI CO. 386-02271) at 
37 °C for 15 min.45 Dispersed islet cells were incubated at 37 °C overnight and then 
stained with a phycoerythrin (PE)-anti mouse IgG2a antibody (isotype control; 
BioLegend 400211) or PE anti-mouse H-2Kd/H-2Dd antibody (BioLegend 114708). 
The cells were analyzed by a BD FACSVerse (BD Biosciences) and FlowJo software 
(Tree Star Inc.).  
MLR 
After inducing immunological sensitization, T cells were isolated from the spleens of 
recipient C57BL/6J mice using nylon wool fiber columns (Polysciences, Inc. 21759-1), 
incubated with carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen C34554) at 
37 °C for 15 min, and then used as responder cells. Spleen cells obtained from naive 
BALB/c mice were pretreated with 25 μg/mL mitomycin C (Sigma-Aldrich Co. M4287) 
at 37 °C for 1 h. Then, BALB/c spleen cells were treated with 0, 1, or 10 mg/mL 
papain at 37 °C for 15 min and used as stimulator cells. The responder cells 
(C57BL/6J, 1×105 cells) were cultured in the presence of stimulator cells (BALB/c, 
1×105 cells) in RPMI 1640 (Thermo Fisher Scientific 22400-089) supplemented with 
10% fetal bovine serum, 55 M 2-mercaptoethanol (Thermo Fisher Scientific 
21985-023) and 100 U/mL penicillin, and 100 g/mL streptomycin (Thermo Fisher 
Scientific 15140-122) in 96-well V-bottomed plates (total volume: 200 μl at 37 °C in a 
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humidified atmosphere with 5% CO2) and collected after 24, 48, 72 or 96 h of 
incubation. A PerCP/Cy5.5-conjugated anti-mouse CD3 antibody (BioLegend 
100218) was used to determine CD3+ T cells, and then the CD3+-gated cell 
population was assessed by flow cytometric analysis at 24, 48, 72, and 96 h to detect 
changes in CFSE fluorescence. MTT assays were also performed as a quantitative 
analysis of proliferation using the Cell Counting Kit-8 after incubation for 72 h. 
Islet viability assay 
After culture for 24 h, isolated islets were treated with 0, 0.1, 1 or 10 mg/mL papain at 
37 °C for 15 min. The islets were then stained with annexin V-FITC and propidium 
iodide (PI; TREVIGEN, Inc. 4830-01) to evaluate the number of apoptotic and 
necrotic cells, together with 4', 6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich Co. 
D9564) for nuclear staining. Isolated islets treated with 0, 0.1, 1 or 10 mg/mL papain 
were also stained with Hoechst 33342 and PI, and then the percentage of viable islet 
cells (viability) at each papain concentration was calculated using an average of ten 
islets. Viability (%) was calculated by subtracting the PI-positive ratio from 100. 
Statistical analysis 
Survival data were analyzed using GraphPad Prism 6 statistic software and shown by 
Kaplan-Meier methods. Islet graft survival between experimental groups was 
compared using the Log-rank test. All data were statistically assessed by one-way 
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analysis of variance, followed by the Tukey-Kramer test to compare two groups. 
P-values less than 0.05 was considered to be statistically significant.  
Abbreviations 
MHC  major histocompatibility complex. 
MLR  mixed lymphocyte reaction. 
MST  median survival time. 
MTT  3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide. 
Treg  regulatory T cell. 
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TABLE1. Graft survival of BALB/c islets pretreated with papain in C57BL/6J 
recipients 
 
*Median survival times 
  
Group n Graft survival (days) MST* (days) 
Papain 0 mg/mL 10 14, 14, 16, 17, 19, 19, 21, 24, 26, 34 19 
Papain 0.1 mg/mL 10 14, 15, 17, 17, 19, 19, 19, 24, 120<, 120< 19 
Papain 1 mg/mL 11 17, 21, 21, 25, 25, 26, 31, 71, 120<, 120 <, 120<   26 
Papain 10 mg/mL 5 12, 12, 12, 14, 18 12 
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FIGURE 1. Effect of papain pretreatment on islet allograft survival Isolated 
BALB/c islets were pretreated with various papain concentrations (0, 0.1, 1, and 10 
mg/mL) prior to islet transplantation. Two hundred islets were transplanted under the 
left KC. A. Individual blood glucose readings for a cohort of papain-pretreated 
islet-transplanted C57BL/6J mice. As indicated by the arrow, nephrectomies were 
performed on recipient mice that survived up to 120 days after receiving an islet 
allograft. B. Survival of islet allografts (BALB/c to C57BL/6J) in recipient mice. The 
MSTs were calculated and compared using the Kaplan-Meier method. C. Histological 
analysis of the grafts of 0 and 1 mg/mL papain groups (upper panels: 0 mg/mL papain 
(day 14); middle: 1 mg/mL papain (day 14); lower: 1 mg/mL papain (day 120)) Islet 
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grafts were harvested on days 14 or 120 after transplantation. Paraffin-embedded 
sections were stained with HE, and anti-insulin and -Foxp3 antibodies. Arrowheads 
indicate Foxp3-positive cells. (HE and insulin staining: original magnification, ×100; 
Foxp3 staining: left, ×200 and right, ×400) 
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FIGURE 2. Effects of papain pretreatment of isolated islets on prevention of 
lymphocyte proliferation against islet alloantigens Prior to the lymphocyte 
proliferation assay in vitro, BALB/c mouse islets were transplanted into C57BL/6J 
recipient mice to induce immunological sensitization. Ten days after transplantation, a 
lymphocyte proliferation assay was used to examine the proliferative response of the 
recipient spleen-derived lymphocytes to donor single islet cells (BALB/c). Proliferation 
of lymphocyte was measured by MTT assays after 24, 48, 72, 96, and 120 h of 
culture. The result of each well is presented as the mean±SD (n=7). The experiment 
was repeated three times. *p<0.001 compared with the corresponding 0 papain 
mg/mL group. 
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FIGURE 3. MHC class I expression on papain-pretreated islet cells Flow 
cytometric analysis of MHC class I on papain-treated islet cells. Donor islets (BALB/c) 
were dissociated into single cells and treated with 0, 1, 10 mg/mL papain at 37 °C for 
15 min. Then, the dispersed islet cells were stained for MHC class I. The histograms 
are indicative of representative data of three separate experiments. 
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FIGURE 4. Effects of papain pretreatment on the reduction of an MLR Prior to T 
cell proliferation assays in vitro, BALB/c mouse islets were transplanted into 
C57BL/6J recipient mice to induce immunological sensitization. Ten days after 
transplantation, MLRs were performed to examine the proliferative response of the 
recipient spleen-derived T cells to donor-type spleen cells (BALB/c). A. 
Time-dependent change of CD3+ T cell proliferation detected by flow cytometric 
analysis of CFSE-stained cells. The black shadowed area represents CD3+ T cell 
proliferation at 24 h, while the three other linear histograms represent the cell 
proliferation at 48, 72, and 96 h. A representative histogram of three samples is 
shown. B. The MLR was also analyzed by an MTT assay after incubation for 72 h. 
The result of each well is presented as the mean±SD (n=8). The experiment was 
repeated three times. *p<0.05, **p<0.01.  
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FIGURE 5. Effect of Papain on islet cell viability Fluorescence photomicrographs 
of isolated donor islets (BALB/c) treated with 0, 0.1, 1, and 10 mg/mL papain (37 °C, 
15 min). A. Islets were stained with annexin V-FITC (green), PI (red), and DAPI (blue) 
to reveal the number of viable, necrotic, and apoptotic cells. B. Islets were stained 
with Hoechst 33342 and PI. The percentage of viable islet cells (viability) in each 
condition was calculated by the average of ten islets. Viability (%) =100-PI-positive 
ratio.  
 
 
 
